8-K: Shattuck Labs Launches $75M At-The-Market Offering

Shattuck Labs, Inc. has entered into a sales agreement with Leerink Partners LLC to offer and sell up to $75 million of its common stock through an at-the-market offering.

Summary

• Shattuck Labs, Inc. (the Company) has established an "at-the-market" (ATM) equity offering program with Leerink Partners LLC as its sales agent.
• The Company may offer and sell from time to time shares of its common stock, with an aggregate value of up to $75,000,000.
• Sales of shares, if any, will be made at market prices by any method deemed an at-the-market offering as defined in Rule 415(a)(4) under the Securities Act.
• The Company has no obligation to sell any shares and retains the right to suspend offers or terminate the Sales Agreement at any time.
• Proceeds from the offering are intended to advance ongoing and planned clinical trials, develop additional product candidates, and for working capital and general corporate purposes.
• Leerink Partners LLC will receive a commission of up to 3.0% of the gross sales price of the shares sold through it, and the Company will reimburse certain expenses.

Sentiment

Score: 7

Explanation: The filing indicates a proactive step by Shattuck Labs to secure flexible funding for its clinical development and operations, which is generally positive for a biotech company. However, the potential for shareholder dilution and the costs associated with the offering introduce some moderate negative aspects.

Positives

• Provides Shattuck Labs with flexible access to capital of up to $75 million, allowing for opportunistic fundraising based on market conditions.
• The capital raised is intended to fund critical activities, including advancing ongoing and planned clinical trials and developing additional product candidates.
• Strengthens the Company's financial position for general corporate purposes and working capital.

Negatives

• Potential for dilution of existing shareholders as new common stock shares are offered and sold into the market.
• The Company will incur commissions of up to 3.0% of gross sales, plus certain expenses, which will reduce the net proceeds received from the offering.

Risks

• There is no assurance that the Agent will be successful in selling Placement Shares, and the Agent incurs no liability if sales are not made, except for failure to use commercially reasonable efforts.
• The Sales Agreement may be terminated by the Agent if a material adverse effect occurs or is reasonably expected, which could materially impair the Agent's ability to sell shares.
• The Company's ability to issue and sell shares is subject to limitations, including the number of shares registered, authorized but unissued shares, and Form S-3 eligibility requirements.
• The Company is restricted from selling Placement Shares below a minimum price authorized by its board of directors.

Future Outlook

The Company intends to use the proceeds from the offering to advance its ongoing and planned clinical trials and to develop and advance additional product candidates, as well as for working capital and general corporate purposes.

Industry Context

This ATM offering provides Shattuck Labs with a flexible financing mechanism common in the biotechnology industry, allowing it to fund its R&D pipeline and clinical development without the immediate pricing pressure of a traditional underwritten offering. This approach is often favored by growth-stage biotech companies to manage capital needs as they progress through costly clinical trial phases.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock. However, the capital raise supports future growth and development, which could benefit long-term shareholder value.
• Employees: Continued funding for clinical trials and product development may provide job security and opportunities within the company.
• Customers/Patients: Funding for clinical trials aims to advance product candidates, potentially leading to new treatments.
• Creditors: A capital raise strengthens the company's financial position, potentially reducing credit risk.

Next Steps

• The Company may, from time to time, offer and sell shares of common stock through Leerink Partners LLC.
• Proceeds from any sales will be used to advance ongoing and planned clinical trials and develop additional product candidates.
• The Company will file prospectus supplements with the SEC detailing the number of shares sold, net proceeds, and compensation.

Key Dates

Keywords

Shattuck Labs, STTK, At-The-Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, Leerink Partners, Clinical Trials, Biotechnology, SEC Filing, Form S-3, Dilution